SDGR vs RXRX vs ABSI vs RLAY vs CDNS

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Cadence Design Systems, Inc. (CDNS) offers the better valuation at 87. 9x trailing P/E (45. 0x forward), making it the more compelling value choice. Analysts rate Schrödinger, Inc. (SDGR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cadence Design Systems, Inc.

(CDNS) delivered a total return of +176. 6%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: CDNS returned +1412% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cadence Design Systems, Inc.

(CDNS) is the lower-risk stock at 1. 48β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 114% more volatile than CDNS relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 45% for Cadence Design Systems, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Schrödinger, Inc. grew EPS 45. 1% year-over-year, compared to 5. 5% for Cadence Design Systems, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cadence Design Systems, Inc.

(CDNS) is the more profitable company, earning 20. 9% net margin versus -41. 1% for Absci Corporation — meaning it keeps 20. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNS leads at 31. 1% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — CDNS leads at 86. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RXRX: 236.

4% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cadence Design Systems, Inc.

(CDNS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1412% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNS: +1412%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SDGR (Healthcare) and RXRX (Healthcare) and ABSI (Healthcare) and RLAY (Healthcare) and CDNS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SDGR is a small-cap high-growth stock; RXRX is a small-cap high-growth stock; ABSI is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock; CDNS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.